X4 Pharmaceuticals Advances with Strategic Financial Moves

X4 Pharmaceuticals Inc (XFOR) has provided an update.

X4 Pharmaceuticals, Inc. successfully sold a Rare Pediatric Disease Priority Review Voucher for $105 million in cash, following the FDA’s approval of their treatment for WHIM syndrome. Additionally, the company’s CFO, Adam Mostafa, was awarded a $102,000 bonus for his key role in the transaction. The company also announced taking an additional $20 million from its loan facility, signaling robust financial activity and strategic moves to stakeholders in the pharmaceutical industry.

Learn more about XFOR stock on TipRanks’ Stock Analysis page.